 Genprex Inc has announced a plan to accelerate the opening of trial sites for the Acclaim-1 clinical trial, which combines the companys lead product candidate, REQORSA quaratusugene ozeplasmid Immunogene Therapy, with AstraZenecas Tagrisso as a potential innovative treatment for non-small cell lung cancer NSCLC. The company said the opening of four clinical trial sites to enroll patients in the Phase 1 portion of Genprexs Acclaim-1 clinical trial is underway as part of a collaboration agreement with a large network of integrated, community-based oncology practices, with an expectation of opening additional sites in the Phase 2 portion of the study. 